Sharon Fisher v. Boehringer Ingelheim International GMBH
Opinion
trial_court Opinion
1 2 3 4 UNITED STATES DISTRICT COURT 5 NORTHERN DISTRICT OF CALIFORNIA 6 7 SHARON FISHER, Case No. 24-cv-00057-TLT
8 Plaintiff,
ORDER DISMISSING CASE
v. 9 Re: Dkt. No. 30 10 BOEHRINGER INGELHEIM INTERNATIONAL GMBH, et al., 11 Defendants.
12 13 Before the Court is Plaintiff’s Motion to Dismiss (“Motion”), ECF No. 30. Plaintiff filed 14 this suit in state court in early 2023—alleging that Defendants’ product gave her breast cancer— 15 and Defendants GlaxoSmithKline LLC, Boehringer Ingelheim Pharmaceuticals, Inc., and Pfizer 16 Inc. (collectively, “Brand Defendants”) removed to this Court in early 2024. See Notice of 17 Removal ¶ 3, ECF No. 1; id. Ex. A, ¶ 13, ECF No. 1-2. Days later, a conditional transfer order 18 was entered in MDL No. 2924, which Plaintiff opposed. See In re Zantac (Ranitidine)Prods. 19 Liab. Litig., MDL No. 2924, ECF Nos. 1375, 1378. Plaintiff now moves to dismiss without 20 prejudice under Federal Rule of Procedure 41(a)(2), citing her poor health and the burdens of 21 litigation. Mot. 1. 22 Under Rule 41(a)(2), “an action may be dismissed at…